Parkinson's Disease - Review of Key Commercial Opportunities in the Symptomatic Treatment Market

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2006-07-25

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Parkinson's disease (PD) is a progressive, degenerative condition of the central nervous system (CNS), caused by the degeneration of dopaminergic neurons in the substantia nigra of the midbrain. The PD market grew by 6.9% to $1.8 billion between 2004 and 2005. In the absence of conclusive evidence for a neuroprotective compound, the focus on the market remains on symptomatic treatment.


Scope

  • Assessment of patient size across the seven major markets (US, Japan, France, Germany, Italy, Spain, UK) including prevalence of co-morbid conditions.
  • Overview of Parkinson's disease market dynamics, discussing market share across the seven major markets, drug classes and brands.
  • Qualitative interviews with key international opinion leaders.
  • Case study analysis of new market entrants which target different disease stages, leading to recommendations to companies entering the market.


    • Report Highlights
    Manufacturers of neuroprotective products will benefit from driving research and awareness of new diagnostic technologies such as genetic testing to better identify patients in the very early stages of PD or those at risk of the disease.

    Companies developing improved delivery technologies including continuous transdermal dopamine agonist stimulation and smooth delivery of levodopa will be at a competitive advantage and that novel formulations will become an increasingly important product differentiating strategy.

    The major unmet need in the treatment in advanced PD is the reduction of OFF periods. Few companies have investigated this area since advanced patient opportunities represent a very small market and Vernalis' Apokyn (apomorphine) is presently the only drug available for this specific use.


    Reasons to Purchase

  • Understand key opinion leaders (KOL) views on hot issues in Parkinson's disease diagnosis, treatment, and unmet needs.
  • Identify the opportunities and threats for Azilect (rasagiline), Neupro (rotigotine CDS), and Apokyn (apomorphine) in the market.
  • Identify future challenges to Parkinson's disease drugs and best method of overcoming these.

    • Table of Contents

    Other users found this report page using the following search terms: neuroprotection neurodegeneration neurodegenerative parkinsons off label use neupro key opinion leaders kol measure

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.